lunes, 1 de junio de 2020

COVIDView: A Weekly Surveillance Summary of U.S. COVID-19 Activity | CDC

COVIDView: A Weekly Surveillance Summary of U.S. COVID-19 Activity | CDC

COVIDView: A Weekly Surveillance Summary of U.S. COVID-19 Activity

Key Updates for Week 21, ending May 23, 2020

Nationally, levels of influenza-like illness (ILI) and COVID-19-like illness (CLI) and the percentage of specimens testing positive for SARS-CoV-2, the virus that causes COVID-19, continue to decline or remain stable.  Mortality attributed to COVID-19 also decreased compared to last week but remains elevated above baseline and may increase as additional death certificates are processed.

Virus

Public Health, Commercial and Clinical Laboratories

The national percentage of respiratory specimens testing positive for SARS-CoV-2 at public health, clinical and commercial laboratories decreased from week 20 to week 21; however, percent positivity increased slightly in two regions. National percentages by type of laboratory:
  • Public health laboratories – decreased from 8.4% during week 20 to 7.0% during week 21;
  • Clinical laboratories – decreased from 6.3% during week 20 to 5.6% during week 21;
  • Commercial laboratories – decreased from 7.8 % during week 20 to 6.9% during week 21.

Outpatient and Emergency Department Visits

Outpatient Influenza-Like Illness Network (ILINet) and National Syndromic Surveillance Program (NSSP)

Two surveillance indicators are being used to track outpatient or emergency department (ED) visits for illness with symptoms compatible with COVID-19.
  • Nationally, the percentages of visits for ILI and CLI decreased or remained stable at low levels, compared to last week. Levels of ILI are below baseline nationally for the sixth week and in all 10 surveillance regions for the past four to seven weeks.
Recent changes in health care seeking behavior, including increasing use of telemedicine, recommendations to limit emergency department (ED) visits to severe illnesses, and increased practice of social distancing, are likely affecting data reported from both networks, making it difficult to draw conclusions at this time. Tracking these systems moving forward will give additional insight into illness related to COVID-19.

Severe Disease

Hospitalizations

Cumulative COVID-19-associated hospitalization rates since March 1, 2020, are updated weekly. The overall cumulative COVID-19 hospitalization rate is 73.3 per 100,000, with the highest rates in people aged 65 years and older (229.7 per 100,000) and 50-64 years (113.4 per 100,000).

Mortality

Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza or COVID-19 (PIC) decreased from 15.9% during week 20 to 9.8% during week 21 but remained above baseline. This is the fifth week of a declining percentage of deaths due to PIC, but this percentage may change as more death certificates are processed, particularly for recent weeks.
All data are preliminary and may change as more reports are received.
A description of the surveillance systems summarized in COVIDView, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.

Key Points

  • Nationally, the percentages of laboratory specimens testing positive for SARS-CoV-2 with a molecular assay decreased compared to last week; however, there are two developments in particular worth noting:
    • The percent positivity increased slightly in two HHS surveillance regions (Regions 4 [the southeast] and 10 [the Pacific northwest]).
    • While the number of specimens from children <18 years of age tested is low (<5% of all specimens tested in public health and commercial laboratories), the percentage testing positive for SARS-CoV-2 in this age group has either trended upward or remained relatively stable in recent weeks. Other age groups have seen declines in percent positivity during the same time period.
  • Nationally, visits to outpatient providers and emergency departments (EDs) for illnesses with symptoms consistent with COVID-19 continued to decline or remain stable at low levels. Outpatient ILI visits are below baseline nationally and in all regions of the country.
    • The decrease in the percentage of people presenting for care with ILI and CLI may be due to a decline in COVID-19 illness, which could be in part a result of widespread adoption of social distancing, in addition to decreases in healthcare seeking behavior.
    • There has been very little influenza virus activity in recent weeks.
  • The overall cumulative COVID-19 associated hospitalization rate is 73.3 per 100,000, with the highest rates in people 65 years of age and older (229.7 per 100,000) followed by people 50-64 years (113.4 per 100,000). Hospitalization rates are cumulative and will increase as the COVID-19 pandemic continues.
    • This week’s report presents additional information on racial and ethnic disparities among reported COVID-19 hospitalizations. Non-Hispanic Black and non-Hispanic American Indian/Alaska Native populations have rates approximately 4.5 times that of non-Hispanic Whites, while Hispanic/Latinos have a rate approximately 3.5 times that of non-Hispanic Whites.
    • Cumulative hospitalization rates for COVID-19 in adults (18-64 years) at this time are higher than cumulative end-of-season hospitalization rates for influenza over each of the past 5 influenza seasons.
    • For people 65 years and older, current cumulative COVID-19 hospitalization rates are within ranges of cumulative influenza hospitalization rates observed at comparable time points* during recent influenza seasons.
    • For children (0-17 years), cumulative COVID-19 hospitalization rates are much lower than cumulative influenza hospitalization rates at comparable time points* during recent influenza seasons.
  • Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza or COVID-19 (PIC) decreased from 15.9% during week 20 to 9.8% during week 21 but remained above baseline. This is the fifth week during which a declining percentage of deaths due to PIC has been recorded. The percentage remains above the epidemic threshold, and is now similar to what has been observed at the peak of some influenza seasons. The percentage may change as additional death certificates for deaths during recent weeks are processed.
*Number of weeks since 10% of specimens tested positive for SARS-CoV-2 and influenza, respectively.

U.S. Virologic Surveillance

The number of specimens tested for SARS-CoV-2 using a molecular assay and reported to CDC by public health laboratories and a subset of clinical and commercial laboratories in the United States are summarized below. All laboratories are performing primary diagnostic functions; therefore, the percentage of specimens testing positive across laboratory types can be used to monitor overall trends in COVID-19 activity. As the outbreak progresses, it is possible that different types of laboratories will take on different roles, and the data interpretation may need to change. The lower percentage of specimens testing positive in clinical laboratories compared to public health and commercial laboratories may be influenced by COVID-19 activity in areas with reporting laboratories and by larger proportions of specimens obtained from children tested in these laboratories.
Summary of Laboratory Testing Results Reported to CDC
Summary of Laboratory Testing Results Reported to CDC*Week 21
(May 17 – May 23, 2020)
Cumulative since March 1, 2020
No. of specimens tested1,171,5468,762,465
     Public Health Laboratories182,0091,227,717
          Clinical Laboratories72,256740,691
          Commercial Laboratories917,2816,794,057
No. of positive specimens (%)79,898 (6.8%)1,145,733 (13.1%)
     Public Health Laboratories12,702 (7.0%)153,579 (12.5%)
          Clinical Laboratories4,041 (5.6%)60,520 (8.2%)
          Commercial Laboratories63,155 (6.9%)931,634 (13.7%)
* Commercial and clinical laboratory data represents select laboratories and does not capture all tests performed in the United States.

Public Health Laboratories

View Data Table

Clinical Laboratories

View Data Table

Commercial Laboratories

* Commercial laboratories began testing for SARS-CoV-2 in early March, but the number and geographic distribution of reporting commercial laboratories became stable enough to calculate a weekly percentage of specimens testing positive as of March 29, 2020.

View Data Table

Additional virologic surveillance information: Surveillance Methods

Outpatient/Emergency Department Illness

Two syndromic surveillance systems are being used to monitor trends in outpatient and emergency department visits that may be associated with COVID-19 illness. Each system monitors a slightly different syndrome, and together these systems provide a more comprehensive picture of mild to moderate COVID-19 illness than either would individually. Both systems are currently being affected by recent changes in healthcare seeking behavior, including increased use of telemedicine, compliance with recommendations to limit emergency department (ED) visits to severe illnesses, and increased practice of social distancing. These changes affect the numbers of people seeking care in the outpatient and ED settings and their reasons for doing so.

ILINet

The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) provides data on visits for influenza-like illness (ILI) (fever [≥100○F] and cough and/or sore throat) to approximately 2,600 primary care providers, emergency departments and urgent care centers in all 50 states, Puerto Rico, the District of Columbia and the U.S. Virgin Islands. Mild COVID-19 illness presents with symptoms similar to ILI, so ILINet is being used to track trends of mild to moderate COVID-19 illness and allows for comparison with prior influenza seasons.
Nationwide during week 21, 1.0% of patient visits reported through ILINet were due to ILI. This percentage is low and below the national baseline of 2.4% and represents the ninth week of decline after three weeks of increase beginning in early March. Compared to week 20, the percentage of visits for ILI in week 21 decreased slightly among all age groups. Nationally, laboratory-confirmed influenza activity as reported by clinical laboratories is at levels usually seen during summer months which, along with changes in healthcare seeking behavior and the impact of social distancing, is likely contributing to the low level of ILI activity.
* Age-group specific percentages should not be compared to the national baseline.
On a regional levelexternal icon, the percentage of outpatient visits for ILI ranged from 0.4% to 1.5% during week 21. Compared to week 20, the percent of outpatient visits for ILI decreased or remained stable at low levels in all ten regions and all regions are below their region-specific baselines.
Note: In response to the COVID-19 pandemic, new sites will be enrolled in ILINet throughout the summer.  This will result in an increase in patient visits and the percentage of visits for ILI may change in comparison to previous weeks. During week 21, new sites were added in Regions 1, 4, and 6. While these regions remain below baseline levels for ILI, these system changes should be kept in mind when drawing conclusions from these data. Any changes in ILI due to changes in respiratory virus circulation will be highlighted here.

Overall Percentage of Visits for ILI | Age Group ILI Data

ILI Activity Levels

Data collected in ILINet are used to produce a measure of ILI activity for all 50 states, Puerto Rico, the District of Columbia and New York City. The mean reported percentage of visits due to ILI for the current week is compared to the mean reported during non-influenza weeks, and the activity levels correspond to the number of standard deviations below, at or above the mean.
The number of jurisdictions at each activity level during week 21 and the change compared to the previous week are summarized in the table below and shown in the following maps. The decreasing percentage of visits for ILI described above are reflected in this week’s ILI activity levels.
ILI Activity Levels
Activity LevelNumber of Jurisdictions
Week 21
(Week ending May 23, 2020)
Compared to Previous Week
Very High0No change
High1No change
Moderate0-2
Low2No change
Minimal49+1
Insufficient Data2+1
*Data collected in ILINet may disproportionally represent certain populations within a state and may not accurately depict the full picture of influenza activity for the whole state. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

National Syndromic Surveillance Program (NSSP): Emergency Department (ED) Visits

NSSP is a collaboration among CDC, federal partners, local and state health departments and academic and private sector partners to collect, analyze and share electronic patient encounter data received from multiple healthcare settings. To track trends of potential COVID-19 visits, visits for COVID-19-like illness (CLI) (fever and cough or shortness of breath or difficulty breathing or presence of a coronavirus diagnosis code) and ILI to a subset of emergency departments in 47 states are being monitored.
Nationwide during week 21, 2.2% of emergency department visits captured in NSSP were due to CLI and 0.7% were due to ILI. This is the ninth week of decline in the percentage of visits for ILI and the seventh week of declining percentage of visits for CLI. Compared to week 20, all 10 HHS regionsexternal icon had declining percentages of visits for CLI during week 21; all 10 regions also had declining or stable percentages of visits for ILI.
Additional information about medically attended outpatient and emergency department visits for ILI and CLI: Surveillance Methods

Hospitalizations

The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in select counties participating in the Emerging Infections Program (EIP) and the Influenza Hospitalization Surveillance Project (IHSP).
A total of 23,811 laboratory-confirmed COVID-19-associated hospitalizations were reported by sites between March 1, 2020, and May 23, 2020. The overall cumulative hospitalization rate was 73.3 per 100,000 population. Among the 0-4 years, 5-17 years, 18-49 years, 50-64 years, and ≥ 65 years age groups, the highest rate of hospitalization is among adults aged  65 years (229.7 per 100,000), followed by adults aged 50-64 years (113.4 per 100,000) and adults aged 18-49 years (41.0 per 100,000).
Within the 18-49 years and ≥ 65 years age groups, the hospitalization rates increased with increasing age.
Hospitalization Rates
Age GroupCumulative Rate per 100,000 Population
Overall
73.3
     0-4 years
4.1
     5-17 years
1.9
     18-49 years
41.0
  18-29 years
20.1
  30-39 years
40.7
  40-49 years
68.5
    50-64 years
113.4
    65+ years
229.7
  65-74 years
167.6
  75-84 years
276.2
  85+ years
426.7
Among the 23,811 laboratory-confirmed COVID-19-associated hospitalized cases, 19,775 (83%) had information available on race and ethnicity while collection of race and ethnicity data was still pending for 4,036 (17%) cases. Of the 19,775 cases with race and ethnicity data, 35.6% were non-Hispanic White, 34.1% were non-Hispanic Black, 17.9% were Hispanic/Latino, 4.5% were non-Hispanic Asian/Pacific Islander, 1.4% were non-Hispanic American Indian/Alaska Native, 0.2% were multiple race, and 6.3% had unknown race. In comparison, the COVID-NET catchment area population includes 58.8% non-Hispanic White, 17.7% non-Hispanic Black, 14.0% Hispanic/Latino, 8.8% non-Hispanic Asian/Pacific Islander, and 0.7% non-Hispanic American Indian/Alaska Native residents. Additional data on race and ethnicity by age are available.
COVID-19-associated hospitalization rates by race and ethnicity are calculated using hospitalized COVID-NET cases with known race and ethnicity for the numerator and NCHS bridged-race population estimates for the denominator. Rates are adjusted to account for differences in age distributions within race and ethnicity strata in the COVID-NET catchment area; the age strata used for the adjustment include 0-17, 18-49, 50-64, 75-84, and ≥85 years. Age-adjusted hospitalization rates are highest in non-Hispanic American Indian/Alaska Native and non-Hispanic Black populations, followed by Hispanic/Latino. Non-Hispanic Black and non-Hispanic American Indian/Alaska Native populations have a rate approximately 4.5 times that of non-Hispanic Whites, while Hispanic/Latinos have a rate approximately 3.5 times that of non-Hispanic Whites.
Among 5,187 hospitalized adults with information on underlying medical conditions, 91.7% had at least one reported underlying medical condition, the most commonly reported were hypertension, obesity, chronic metabolic disease, and cardiovascular disease.
Additional hospitalization surveillance information: Surveillance Methods  | Additional rate data  |  Additional demographic and clinical data

Mortality Surveillance

The National Center for Health Statistics (NCHS) collects death certificate data from vital statistics offices for all deaths occurring in the United States. Based on death certificate data available on May 28, 2020, 9.8% of all deaths occurring during the week ending May 23, 2020 (week 21) were due to pneumonia, influenza or COVID-19 (PIC). This is the fifth week of a declining percentage of deaths due to PIC; however, the percentage remains above the epidemic threshold of 6.4% for week 21. Data for recent weeks are incomplete, and the PIC percentage may increase as more death certificates representing deaths during these weeks are processed.
Weekly mortality surveillance data include a combination of machine coded and manually coded causes of death collected from death certificates.  Percentages of deaths due to PIC are higher among manually coded records than more rapidly available machine coded records. Due to the additional time needed for manual coding, the initially reported PIC percentages may be lower than percentages calculated from final data.
*Data during recent weeks are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes.

View Data Table

Additional NCHS mortality surveillance information: Surveillance Methods  | Provisional Death Counts for COVID-19

The Public Health Impact of COVID-19: Why Host Genomics? | | Blogs | CDC

The Public Health Impact of COVID-19: Why Host Genomics? | | Blogs | CDC

Genomics & Precision Health Weekly Update with DNA

The Public Health Impact of COVID-19: Why Host Genomics?

Posted on  by Muin J. Khoury, Office of Genomics and Precision Public Health, Office of Science, Centers for Disease Control and Prevention, Atlanta, Georgia; Marta Gwinn, CFOL International for Office of Advanced Molecular Detection, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Priya Duggal, Genetic Epidemiology Program, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland

covid-19 virus overlayed on whole genome sequencing with a world map in the background where figures are connected with lines

Throughout human history, zoonotic pandemics have periodically resulted in catastrophic human morbidity and mortality exceeding war, famine, and natural disasters combined. Modern era medicine and public health have made remarkable advances, but vulnerabilities have also increased with unprecedented world population growth, greater interaction with wildlife, and the dramatic expansion of international air travel. Viral diseases from animal populations continue to emerge in the 21st century to cause human epidemics, challenging public health systems around the world. These include previous novel coronavirus disease outbreaks of severe acute respiratory syndrome (SARS; 2002-03) and Middle East respiratory syndrome (MERS; 2012), among many others.
A novel coronavirus that emerged in late 2019 has rapidly become a global pandemic, affecting more than 1 million people worldwide as of April 11, 2020. Evidence suggests that host factors such as age, sex and underlying comorbidities play a role in the risk of severe outcomes of COVID-19, including mortality.

Potential Benefits of Host Genomic Investigations

In the decade following the SARS outbreak in 2003, several human candidate gene studies of infection susceptibility and severity were conducted. Human genome-wide association studies (GWAS) were proposed as a way to investigate the “super-spreader” phenomenon observed in the SARS and MERS outbreaks. Human genetic factors have also been investigated in avian and swine influenza outbreaks, for example in studies of family clustering of H5N1 and pediatric morbidity following H1N1 infection.
Although priority for such research efforts can taper without a sustained commitment, an integrated approach to “research preparedness” includes actions before, during, and after the event. Advances in technology now make it possible to analyze host genomic factors while an outbreak is underway. The ability to quickly and accurately identify vulnerable and protective host factors could expand the effectiveness of the public health approach to COVID-19.
Genome sequencing technologies that identified the SARS coronavirus in 2003 have evolved rapidly in the past two decades. Chinese scientists were able to sequence COVID-19 and post the results online within two weeks of the first reported cases. Research priorities in the current outbreak include devising rapidly deployable diagnostic tests, better understanding transmission, developing and testing antiviral drugs, and ultimately, developing a protective vaccine.
Both viral and human genomic information may be important for achieving these goals. Finding biological mechanisms for severe infection could inform the development of therapeutics targeting those pathways. Information on human genetic variants associated with susceptibility to severe infection could be useful for prevention within families and healthcare workers or for directing clinical care on hospital admission.
Research publications have suggested the potential for ACE2 genetic variants, interleukin-6, HLA antigens, and blood groups to be risk factors in COVID-19 severity and outcomes. Am emerging global COVID-19 host genetics initiative is bringing together the human genetics community “to generate, share and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity and outcomes. Such discoveries could help to generate hypotheses for drug repurposing, identify individuals at unusually high or low risk, and contribute to global knowledge of the biology of SARS-CoV-2 infection and disease severity.”
Ideally, scientific studies of COVID-19 risk factors for transmission and severity should include both viral and human genomes and the interaction of these two genomes, along with other traditional environmental, social and economic factors, and emerging types of “big data”. Together, such studies could not only accelerate our knowledge base but contribute to a new era of precision public health.
Posted on  by Muin J. Khoury, Office of Genomics and Precision Public Health, Office of Science, Centers for Disease Control and Prevention, Atlanta, Georgia; Marta Gwinn, CFOL International for Office of Advanced Molecular Detection, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Priya Duggal, Genetic Epidemiology Program, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland

Tags , 

Genetic Counseling in the Time of COVID-19 | | Blogs | CDC

Genetic Counseling in the Time of COVID-19 | | Blogs | CDC

Genomics & Precision Health Weekly Update with DNA

Genetic Counseling in the Time of COVID-19

Posted on  by Katie Bruder, Genetic Counseling Training Program Class of 2020, Emory University School of Medicine and Ridgely Fisk Green, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia

a hand magnifying DNA on COVID-19 with cellphones, tablets and laptops being connected by figures

Genetic counselors play an important role in clinical genetics by helping patients understand their genetic health risks. Due to the COVID-19 pandemic, most clinics and hospitals have restricted in-person delivery of non-essential healthcare services, including genetic counseling, to slow the spread of the virus. However, delaying genetic counseling can be problematic, for example, when genetic testing would affect decisions during a pregnancy or about cancer treatment. Moreover, genetics and genetic counseling have become integral to healthcare as we learn more and more about genetic risks for disease.
Now that genetic counselors are largely unable to see patients in person due to the COVID-19 pandemic, more genetic counselors are turning to telehealth out of necessity. Telehealth refers to the use of technology to support long-distance healthcare. For example, instead of an office visit, a patient could video chat with a healthcare provider. Many clinics that used a mixture of in-person and telehealth services in the past have now transitioned to using only telehealth services due to the pandemic. However, for clinics that have only seen patients in-person, the transition to using telehealth may present a challenge. Private genetic counseling companies that offer genetic counseling exclusively through telehealth may be able to provide guidance to other genetic counselors or healthcare professionals on how technology can be used to communicate with patients, deliver results, and provide support to patients during this time.
Because of the increased need for telehealth during the COVID-19 pandemic, insurance coverage of distance-based services has become increasingly important. While the Centers for Medicare and Medicaid Services (CMS) has recently expanded telehealth benefits for Medicare beneficiaries, they do not presently recognize genetic counselors as healthcare providers. This means that genetic counselors cannot be reimbursed for their services or see Medicare recipients without a physician present, which presents challenges to providing genetic counseling via telehealth. To improve Medicare recipients’ access to genetic counseling during the COVID-pandemic, the National Society of Genetic Counselors (NSGC) has issued a statement offering some potential short- and long-term solutions.
Thinking ahead to post-pandemic life, telehealth may be used more commonly in genetic counseling in the future. Genetic counselors had used telehealth services long before the pandemic, and there is a trend showing that the use of these services has grown over the past few years. Some healthcare professionals have had concerns about using telehealth, such as the possibility for technical difficulties, privacy concerns, decreased ability to interpret non-verbal cues, and decreased rapport-building. However, studies have shown that patient satisfaction with telehealth genetic counseling services is high. Telehealth has the potential to improve access to services, which is a major benefit in a field where there is a high and growing demand for genetics services. Many genetic counselors consider telehealth to be more convenient than traditional in-person service delivery due to reduced travel times and wait times for patients. In these uncertain times, one thing that seems certain is that telehealth in genetic counseling is here to stay.
Posted on  by Katie Bruder, Genetic Counseling Training Program Class of 2020, Emory University School of Medicine and Ridgely Fisk Green, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, Georgia

Tags , 

Virus may be invisible enemy but COVID warriors invincible: PM Modi | India News,The Indian Express

Virus may be invisible enemy but COVID warriors invincible: PM Modi | India News,The Indian Express

Narendra Modi, Modi on coronavirus, coronavirus India, coronavirus cases, coronavirus latest news, lockdown 5.0

Virus may be invisible enemy but COVID warriors invincible: PM Modi

JUNE 1, 2020 12:44:07 PM
"At the root of India's brave fight against COVID-19 is the hard work of the medical community and our corona warriors. In fact, doctors and medical workers are like soldiers, but without the soldiers' uniforms," PM Modi said.

Coronavirus Cases in India State-wise Today Latest Update, Covid-19 (Corona) Cases Tracker India: Uttar Pradesh Delhi, Maharashtra, Tamil Nadu, Gujarat

Coronavirus Cases in India State-wise Today Latest Update, Covid-19 (Corona) Cases Tracker India: Uttar Pradesh Delhi, Maharashtra, Tamil Nadu, Gujarat

Coronavirus India Updates June 1: India 7th worst-hit country as unlockdown begins today

JUNE 1, 2020 3:01:13 PM
With its biggest single-day spike in Covid-19 infections, India became the world's seventh worst affected country, having over 1,90,500 cases and 5,394 fatalities. India's caseload rose by 8,392 infections along with 230 deaths in the last 24 hours.